Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.88 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.9 | |||||
| 3-Year EPS without NRI Growth Rate | -12.2 | |||||
| 3-Year FCF Growth Rate | -15.5 | |||||
| 3-Year Book Growth Rate | -22.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 64.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.09 | |||||
| 9-Day RSI | 39.61 | |||||
| 14-Day RSI | 41.01 | |||||
| 6-1 Month Momentum % | 2.94 | |||||
| 12-1 Month Momentum % | 38.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.55 | |||||
| Quick Ratio | 8.55 | |||||
| Cash Ratio | 7.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 | |||||
| Shareholder Yield % | 0.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -98.21 | |||||
| ROA % | -83.53 | |||||
| ROIC % | -694.01 | |||||
| ROC (Joel Greenblatt) % | -1573.15 | |||||
| ROCE % | -97.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.51 | |||||
| Price-to-Tangible-Book | 2.51 | |||||
| EV-to-EBIT | -2.22 | |||||
| EV-to-EBITDA | -2.24 | |||||
| EV-to-Forward-Revenue | 17.6 | |||||
| EV-to-FCF | -3.17 | |||||
| Price-to-Net-Current-Asset-Value | 2.64 | |||||
| Price-to-Net-Cash | 2.95 | |||||
| Earnings Yield (Greenblatt) % | -45.05 | |||||
| FCF Yield % | -20.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
KalVista Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.328 | ||
| Beta | -0.18 | ||
| Volatility % | 60.23 | ||
| 14-Day RSI | 41.01 | ||
| 14-Day ATR (€) | 0.324726 | ||
| 20-Day SMA (€) | 9.5025 | ||
| 12-1 Month Momentum % | 38.16 | ||
| 52-Week Range (€) | 7.2 - 15 | ||
| Shares Outstanding (Mil) | 49.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
KalVista Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(STU:4XC1)'s stock price today?
The current price of STU:4XC1 is €9.70. The 52 week high of STU:4XC1 is €15.00 and 52 week low is €7.20.
When is next earnings date of KalVista Pharmaceuticals Inc(STU:4XC1)?
The next earnings date of KalVista Pharmaceuticals Inc(STU:4XC1) is 2024-12-06 Est..
Does KalVista Pharmaceuticals Inc(STU:4XC1) pay dividends? If so, how much?
KalVista Pharmaceuticals Inc(STU:4XC1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers